Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Univ. of Alberta NEU2 compound 543
- Development stage
- Unknown
- Lead developer
- University of Alberta
01
Overview
Univ. of Alberta NEU2 compound 543: sourced facts only. name: "Screening of these inhibitors also identify a selective NEU2 inhibitor 543 (Ki = 2.6 ± 0.6 μM), illustrating that amide bioisostere replacement can identify improved inhibitors for multiple NEU isoenzymes." [PMID:40192541]; target: "Screening of these inhibitors also identify a selective NEU2 inhibitor 543 (Ki = 2.6 ± 0.6 μM), illustrating that amide bioisostere replacement can identify improved inhibitors for multiple NEU isoenzymes." [PMID:40192541]; developer: "Department of Chemistry, University of Alberta, Edmonton, Alberta, T6G 2G2, Canada." [PMID:40192541]
02
Targets
NEU2 (Neuraminidase 2)
Beyond the preview
Go deeper on Univ. of Alberta NEU2 compound 543.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Univ. of Alberta NEU2 compound 543.